Related Image: Optelec Offers Back-to-School Low Vision Tech & Eye Health Tips |
(Date:11/23/2009)..., MAYWOOD, Il. -- A Loyola University Health Syst...betics is morbidly obese -- approximately 100 poun...at 62.4 percent of U.S. adults with Type 2 diabete...Among African American adults with Type 2 diabetes...d obesity among people with diabetes is increasing...
(Date:11/23/2009)..., Alzheimer,s disease is caused by the build-up o...eliminating the protein has been the focus of almo...tating neurodegenerative condition. , But that m...Tel Aviv University,s Department of Physiology and...cent research demonstrates that amyloid-beta is al...
(Date:11/23/2009)..., Life-Science Focused St...on of Marketing and Communication Professionals ,...r 23, 2009 -- LaVoie Group, a life science-focused...that it has received the 2009 MarCom Gold Award in... and judged by the Association of Marketing and Co...
(Date:11/23/2009)...,, LOSANGELES,Nov.23/PRNewswire-FirstCall/--...ythatitsproprietarybrandsof MD@Hand ,target=,_blan...e=, MD@Hand ,target=,_blank,title=, MD@Hand ,> MD@...> MD@Hand ,target=,_blank,title=, MD@Hand ,targe...ank,title=, MD@Hand ,target=,_blank,title=, MD@Han...
(Date:11/23/2009)...,, NurturReceivesAccreditationforFivePopula...ewswire-USNewswire/--ThePopulationHealthImpactInst...asedtoannouncedthatPHII,sBoardofDirectorshasapprov....0(H-TAP(TM))aftertwoyearsofdevelopment.Nurtur(TM)...CTisthefirstorganizationtoreceivetheH-TAPaccredita...
Breaking Medicine News(10 mins):Health News:Diabetics show alarming increase in morbid obesity 2Health News:Upending textbook science on Alzheimer's disease 2Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 2Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 3Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 2Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 3Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 4Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 5Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 6Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 7Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3(Date:11/23/2009)...tCall/--Pharmasset,Inc.(Nasdaq: VRUS )announcedtod...SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcontinuefortherem...rialofRG7128,afirst-in-classnucleosideanalogpolyme...us(HCV)infection.Thedecisionwasreachedafteraschedu...C)ofallavailablesafetydatafromthefirstcohortofappr...
(Date:11/23/2009)...irstCall/--Oceanside Pharmaceuticals ,partofValean...nnouncedthatithasnowlaunchedchlordiazepoxidehydroc...versionofLibrax®.Oceansidehasreceiveditsfirst...#174;genericmarket. ,, "Valeant,sOceansideunith...ssuccessfullaunchanddistributionof5%fluorouracil,V...
(Date:11/23/2009)...ancedSterilizationProducts(ASP),aleadingglobalinfe...cquisitionbyitsFrenchaffiliate,ApsisS.A.S.,ofGlost...ectionprocessesandtechnologiestopreventhealthcare-...closed. ,, GlosterEuropedesignsandmarketsaninno...infectionofpatientenvironmentssuchashospitalandope...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Oceanside Pharmaceuticals Announces Launch of Librax(R) AG 2ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2Grant received for eye disorder research 50639 1Grant received for eye disorder research 50639 2FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 1FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 2FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 3FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 4FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 5FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 6FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 7Lixte Biotechnology Holdings Lead Compound LB 1 2 Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models 12880 1Lixte Biotechnology Holdings Lead Compound LB 1 2 Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models 12880 2Lixte Biotechnology Holdings Lead Compound LB 1 2 Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models 12880 3...th factor binding protein-2 (IGFBP-2) is one of si...roposed) which specifically bind and modulate the ...of IGFBP-2 for IGF-II is estimated to be significa...in regulation of IGF-II action. Studies in the fet...
...ric proteins that suppress the secretion of FSH (f...nhibin consists of two distinct chains, or subunit...sists of the alpha-subunit and betaA-subunit. Inhi...nit. Only the dimeric forms of the molecule, conta...
...tor II (IGF-II) is a 7.5 kDa peptide which is secr...ave mitogenic and metabolic actions involved in ce...by binding to target cell receptors. IGF-II binds ...monomeric protein which also serves as the recepto...
...asma protein A (PAPP-A) is a large placenta-derive...centrations by placental trophoblast cells, and is...ing concentrations throughout gestation until deli...e measurable levels have been found in non-pregnan...
Medicine Products: